Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 6, 2024
Deals
Dealmaking in a drought crowns Gracell, Proteologix BayHelix winners
M&A and licensing deals feature prominently in nearly all categories of this year’s BayHelix Awards
BioCentury | Oct 3, 2024
Discovery & Translation
Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight
BioCentury’s roundup of translational innovations
BioCentury | May 20, 2024
Deals
Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies
Plus: Erasca strikes two deals for RAS-targeting therapies, AZ plans new ADC manufacturing site, and more
BioCentury | May 16, 2024
Deals
With Proteologix takeout, J&J adds bispecifics for atopic dermatitis, asthma
Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it
BioCentury | May 4, 2021
Emerging Company Profile
Cytoki’s IL-22 program wins support from European syndicate in $45M series A, moves toward clinic for IBD
Emerging Company Profile: Ex-Novo employee leads spinout seeded by Lundbeckfonden
Items per page:
1 - 10 of 47